Table 4.
Final regression models (SF 36 domains)
| Dimensions | Variables | β coeff. | 95% CI | P values |
|---|---|---|---|---|
|
PF R2 = 0.31 |
Intercept |
95.4 |
[91.1; 99.6] |
p < .0001 |
| |
Female |
-4.7 |
[-7.6; -1.7] |
p < 0.0018 |
| |
Age ≥ 75 years |
-23.3 |
[-30.4; -16.2] |
p < .0001 |
| |
Low educational (primary or less) |
-7.5 |
[-11.2; -3.8] |
p < .0001 |
| |
Unemployment |
-6.3 |
[-9.4; -3.2] |
p < .0001 |
| |
BMI > 30 (kg/m2) |
-5.8 |
[-10; -1.6] |
p < 0.0065 |
| |
Critical illness in the last 4 weeks |
-8.0 |
[-14.9; -1.1] |
p < 0.0237 |
| |
Diabetes |
-5.6 |
[-10.1; -1] |
p < 0.0163 |
| |
Side effects related to general health |
-17.0 |
[-20.9; -13.1] |
p < .0001 |
| |
Side effects related to mental health |
-6.8 |
[-10.5; -3] |
p < 0.0004 |
| |
Recent surgery |
-9.5 |
[-24.9; 6] |
p < 0.2283 |
| |
Infectious disease in the last 4 weeks |
-4.8 |
[-9.1; -0.4] |
p < 0.0311 |
|
RP R2 = 0.22 |
Intercept |
90.5 |
[82.8; 98.1] |
p < .0001 |
| |
Female |
-6.9 |
[-12.2; -1.6] |
p < 0.0104 |
| |
Age ≥ 75 years |
-20.1 |
[-33.1; -7] |
p < 0.0026 |
| |
Low educational (primary or less) |
-11.4 |
[-18; -4.8] |
p < 0.0007 |
| |
Hospitalization in the last 4 weeks |
-17.9 |
[-27.1; -8.8] |
p < 0.0001 |
| |
Critical illness in the last 4 weeks |
-31.5 |
[-44.8; -18.1] |
p < .0001 |
| |
Infectious disease in the last 4 weeks |
-10.9 |
[-19; -2.9] |
p < 0.0080 |
| |
Side effects related to general health |
-21.5 |
[-28.7; -14.3] |
p < .0001 |
| |
Side effects related to mental health |
-16.0 |
[-22.8; -9.1] |
p < .0001 |
|
BP R2 = 0.23 |
Intercept |
85.3 |
[80.6; 90] |
p < .0001 |
| |
Female |
-4.9 |
[-8.1; -1.6] |
p < 0.0035 |
| |
Age ≥ 75 years |
-8.3 |
[-16.1; -0.4] |
p < 0.0402 |
| |
Low educational (primary or less) |
-6.5 |
[-10.5; -2.5] |
p < 0.0016 |
| |
Infectious disease in the last 4 weeks |
-9.1 |
[-14; -4.3] |
p < 0.0002 |
| |
Side effects related to general health |
-18.7 |
[-23.2; -14.2] |
p < .0001 |
| |
Side effects related to mental health |
-9.7 |
[-14; -5.4] |
p < .0001 |
| |
Side effects related to body modification |
-4.2 |
[-7.7; -0.7] |
p < 0.0193 |
|
MH R2 = 0.24 |
Intercept |
81.1 |
[77.7; 84.6] |
p < .0001 |
| |
Female |
-5.6 |
[-8; -3.3] |
p < .0001 |
| |
Family status (living alone) |
-4.6 |
[-7.2; -1.9] |
p < 0.0007 |
| |
Duration of dialysis > 3 years |
-3.3 |
[-5.8; -0.8] |
p < 0.0087 |
| |
Hospitalization in the last 4 weeks |
-7.7 |
[-11.4; -4] |
p < .0001 |
| |
Side effects related to mental health |
-16.5 |
[-19.5; -13.5] |
p < .0001 |
| |
Side effects related to body modification |
-4.4 |
[-6.9; -1.9] |
p < 0.0005 |
|
RE R2 = 0.18 |
Intercept |
94.8 |
[86.5; 103] |
p < .0001 |
| |
Female |
-6.4 |
[-12; -0.8] |
p < 0.0252 |
| |
Low educational (primary or less) |
-16.8 |
[-24; -9.6] |
p < .0001 |
| |
Age ≥ 75 years |
-11.1 |
[-25.3; 3.2] |
p < 0.1285 |
| |
Family status (living alone) |
-9.1 |
[-15.3; -2.8] |
p < 0.0045 |
| |
Hospitalization in the last 4 weeks |
-17.4 |
[-26.7; -8.1] |
p < 0.0003 |
| |
Infectious disease in the last 4 weeks |
-19.1 |
[-27.6; -10.7] |
p < .0001 |
| |
Side effects related to mental health |
-25.0 |
[-32; -18.1] |
p < .0001 |
|
SF R2 = 0.25 |
Intercept |
90.8 |
[86.8; 94.8] |
p < .0001 |
| |
Female |
-4.9 |
[-7.6; -2.1] |
p < 0.0006 |
| |
Family status (living alone) |
-4.6 |
[-7.8; -1.5] |
p < 0.0036 |
| |
Hospitalization in the last 4 weeks |
-11.8 |
[-16.2; -7.3] |
p < .0001 |
| |
Infectious disease in the last 4 weeks |
-7.2 |
[-11.5; -2.9] |
p < 0.0011 |
| |
Diabetes |
-7.5 |
[-11.5; -3.5] |
p < 0.0002 |
| |
Side effects related to general health |
-11.3 |
[-15; -7.6] |
p < .0001 |
| |
Side effects related to mental health |
-16.4 |
[-20; -12.8] |
p < .0001 |
|
VT R2 = 0.22 |
Intercept |
62.8 |
[59.6; 66.1] |
p < .0001 |
| |
Female |
-2.4 |
[-4.6; -0.1] |
p < 0.0366 |
| |
Hospitalization in the last 4 weeks |
-8.3 |
[-11.8; -4.8] |
p < .0001 |
| |
Side effects related to general health |
-12 |
[-15; -8.9] |
p < .0001 |
| |
Side effects related to mental health |
-11.7 |
[-14.8; -8.7] |
p < .0001 |
| |
Side effects related to body modification |
-3.9 |
[-6.3; -1.4] |
p < 0.0020 |
|
GH R2 = 0.18 |
Intercept |
63.8 |
[62.1; 65.5] |
p < .0001 |
| |
Hospitalization in the last 4 weeks |
-6.1 |
[-10.2; -2] |
p < 0.0038 |
| |
Critical illness in the last 4 weeks |
-7.1 |
[-13.5; -0.7] |
p < 0.0305 |
| |
Diabetes |
-5.4 |
[-9; -1.7] |
p < 0.0038 |
| |
Side effects related to general health |
-11.6 |
[-15.1; -8.1] |
p < .0001 |
| |
Side effects related to mental health |
-7.7 |
[-11.1; -4.2] |
p < .0001 |
| |
Side effects related to body modification |
-5.6 |
[-8.4; -2.9] |
p < .0001 |
| |
Non-compliant |
-6.3 |
[-9.2; -3.4] |
p < .0001 |
|
PCS (R2 = 0.28) |
Intercept |
52.7 |
[50.9; 54.5] |
p < .0001 |
| |
Female |
-1.7 |
[-3; -0.4] |
p < 0.0084 |
| |
Age ≥ 75 years |
-7.7 |
[-11; -4.3] |
p < .0001 |
| |
Low educational (primary or less) |
-3.3 |
[-4.9; -1.7] |
p < .0001 |
| |
Unemployment |
-2.5 |
[-3.8; -1.1] |
p < 0.0003 |
| |
Critical illness in the last 4 weeks |
-5.7 |
[-8.8; -2.6] |
p < 0.0003 |
| |
Infectious disease in the last 4 weeks |
-3.2 |
[-5.1; -1.3] |
p < 0.0012 |
| |
Side effects related to general health |
-9.2 |
[-10.8; -7.5] |
p < .0001 |
|
MCS (R2 = 0.22) |
Intercept |
52.1 |
[50.3; 54] |
p < .0001 |
| |
Female |
-1.7 |
[-3; -0.4] |
p < 0.0113 |
| |
Family status (living alone) |
-2.2 |
[-3.7; -0.7] |
p < 0.0039 |
| |
Hospitalization in the last 4 weeks |
-5.7 |
[-7.8; -3.6] |
p < .0001 |
| |
Side effects related to body modification |
-2.5 |
[-3.9; -1.1] |
p < 0.0005 |
| Side effects related to mental health | -9.3 | [-11; -7.7] | p < .0001 |